| Autor: |
Andersson U; Safety Assessment, Molecular Toxicology, AstraZeneca R&D, Södertälje, Sweden. ulf.s.andersson@astrazeneca.com, Lindberg J, Wang S, Balasubramanian R, Marcusson-Ståhl M, Hannula M, Zeng C, Juhasz PJ, Kolmert J, Bäckström J, Nord L, Nilsson K, Martin S, Glinghammar B, Cederbrant K, Schuppe-Koistinen I |
| Jazyk: |
angličtina |
| Zdroj: |
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2009 Dec; Vol. 14 (8), pp. 572-86. |
| DOI: |
10.3109/13547500903261354 |
| Abstrakt: |
Ximelagatran was developed for the prevention and treatment of thromboembolic conditions. However, in long-term clinical trials with ximelagatran, the liver injury marker, alanine aminotransferase (ALT) increased in some patients. Analysis of plasma samples from 134 patients was carried out using proteomic and metabolomic platforms, with the aim of finding predictive biomarkers to explain the ALT elevation. Analytes that were changed after ximelagatran treatment included 3-hydroxybutyrate, pyruvic acid, CSF1R, Gc-globulin, L-glutamine, protein S and alanine, etc. Two of these analytes (pyruvic acid and CSF1R) were studied further in human cell cultures in vitro with ximelagatran. A systems biology approach applied in this study proved to be successful in generating new hypotheses for an unknown mechanism of toxicity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
